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The Case for Modality-Specific Outcome Measures in
Clinical Trials of Stroke Recovery-Promoting Agents
Steven C. Cramer, MD; Walter J. Koroshetz, MD; Seth P. Finklestein, MD
Abstract—Clinical trials for acute stroke treatments have often used composite clinical rating scales as primary outcome
measures of treatment efficacy. Recent preclinical and clinical studies highlight the opportunity to administer treatments
in the subacute and chronic phase of stroke to promote neurological recovery. Because different neurological deficits
recover to different extents at different rates after stroke, putative stroke recovery-promoting treatments may exert
differential effects on various functional aspects of stroke recovery. For this reason, we propose that the use of
modality-specific outcome measures may be best suited as primary end points in clinical trials of stroke recovery-
promoting agents. The use of such end points may result in a more selective labeling of stroke recovery treatments.
(Stroke. 2007;38:1393-1395.)
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Most patients show spontaneous return of neurologicalfunction after a stroke. Because damaged brain tissue
does not fully regenerate in adult humans, these functional
gains most likely occur on the basis of reorganization or
proliferation of surviving cellular elements in brain,1–6 pro-
cesses that appear to be heavily dependent on age.7 Func-
tional recovery is often incomplete, making stroke a leading
cause of adult disability in the United States.8 Many ischemic
stroke therapies currently undergoing development, including
thrombolysis and neuroprotection, focus on the acute phase of
stroke in an effort to reduce the volume of cerebral infarction.
However, recent preclinical and clinical developments
have also highlighted the potential for reducing poststroke
disability via therapies that target the cellular and molec-
ular processes underlying stroke recovery. Examples of
such treatments include growth factors, cell-based thera-
pies, stimulants and other small molecules, and electrical
and magnetic brain stimulation.9 –19 These are treatments
specifically designed to enhance neurological recovery
after stroke and, accordingly, are distinguished from pre-
ventative, thrombolytic, or acute cytoprotective therapies.
These treatments might augment spontaneously occurring
processes that contribute to recovery of neurological function
after stroke, including new neuronal sprouting and synapse
formation in undamaged regions of brain, and stimulation of
progenitor cell proliferation, migration, and differentiation in
brain.2–4 The importance of a stimulatory environment or
“practice” has also been confirmed in preclinical studies, and
corresponding practice-based therapy programs have been
designed for stroke patients.20,21 Because stroke recovery in
humans commonly occurs during weeks to months after
stroke,22–25 it is conceivable that pharmacological, biological,
or device-based treatments might be usefully applied during
this period. By contrast, most acute stroke treatments cur-
rently undergoing development must be given within hours
after stroke onset to reduce infarct size. This editorial
addresses the specific contention that optimal clinical trial
designs for stroke recovery treatments are likely to differ
in several important respects from those for acute stroke
therapies.
In terms of clinical symptomatology, stroke is a multimo-
dal disease, ie, a single infarct often causes deficits in
multiple domains of neurological functioning. The nature of
stroke deficits is highly dependent on the size and location of
cerebral infarcts.26,27 Such deficits include motor, sensory,
cognitive, attention, language, visual, coordination, and gait
disturbances, among others. Moreover, the extent and rate of
recovery after stroke differs among these different functions.
These points are best illustrated by example. A common
variety of clinical stroke is that caused by thromboembolic
occlusion of the middle cerebral artery (MCA). The vascular
territory of the MCA includes more of the cerebral cortex
controlling arm than leg function. Thus, during recovery
from MCA stroke, patients often regain the ability to walk,
whereas recovery of contralateral arm function may remain
minimal.28 Similarly, after a dominant hemisphere MCA
stroke with aphasia, an auditory comprehension deficit
may clear considerably, whereas spontaneous speech may
remain severely dysarthric and nonfluent.29 A visual neglect
may clear over time, whereas a dense field cut may not.24
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These examples illustrate the point that different neurological
functions recover to different extents after stroke.
Similarly, various neurological functions recover at vary-
ing rates after stroke. Motor function shows the most dra-
matic improvement in the first 30 days;22,23 gains in construc-
tional apraxia may be seen up to 6 months after stroke;
language deficits often show gains for months to years after
stroke onset;25 recovery of visuospatial neglect and anosog-
nosia is usually not complete until 5 months after stroke;24
motor impersistence and extinction often continue to improve
for 9 to 12 months after stroke;24 gait generally improves over
a 14-week period after stroke, although gains may be seen
after this period in patients with accompanying sensory
deficits;30 resolution of urinary incontinence is seen beyond
20 weeks after stroke;30 and cognitive functions often con-
tinue to improve for many months after stroke.31–33 The time
course of recovery in one neurological domain can be
independent of recovery in a second domain of neurological
function.24,34,35
Clinical trials of acute stroke therapies, including
thrombolytic and neuroprotective agents, have generally re-
lied on composite clinical rating scales as primary outcome
measures. Examples of such composite measures include
functional outcome scales, such as the modified Rankin scale
and Barthel Index, and neurologic disability scales, such as
the National Institutes of Health Stroke Scale.36 In this
context, the term composite refers to scales that combine
multiple aspects of neurological functioning, such that a
single score can be applied to describe overall outcome after
stroke. Analysis of such scales in clinical trials has often
relied on dichotomization of “satisfactory” versus “unsatis-
factory” outcome,37,38 or more recently on “shift analysis,”39
to examine differences in distribution of scores among treated
versus untreated patients. The attraction of composite scales
for clinicians, drug developers, and regulatory agencies is
simplicity, because they appear to provide a single score that
succinctly summarizes outcome. Scores on composite scales
are presumed to correlate with quality of life, the most
important, but most difficult to measure, outcome of a
therapeutic intervention.
However, because symptoms of stroke are multimodal, and
because different neurological functions recover to different
degrees at different rates, it seems reasonable to assume that
treatments designed to enhance stroke recovery may also
affect different functions to different degrees at different
rates. As a consequence, composite rating scales may not be
the most appropriate primary outcome measures for clinical
trials of stroke recovery treatments. In particular, with use of
composite scales, a meaningful gain in one domain may be
either obscured or overemphasized by little or no gain in
another, especially if domains are unequally weighted. The
composite scales in common use are weighted more heavily
toward motor than cognitive function, often with special
attention given to the ability to walk. Thus, use of a
motor-weighted composite scale in patients with MCA stroke
may obscure a remarkable recovery of aphasia or neglect,
when meaningful recovery of motor function has not oc-
curred. Similarly, a composite scale may overemphasize
recovery of walking, which often occurs after MCA stroke,
while arm function may remain severely impaired. Indeed,
these two clinical patterns are common clinical experience
after MCA stroke.
Because of these reasons, we propose that “modality-
specific” outcome measures are the most appropriate primary
end points for clinical trials of stroke recovery treatments.
Specifically, well-validated and reproducible measures exist
for the assessment of sensorimotor, gait, language, neglect,
memory, frontal lobe, and neuropsychiatric function after
stroke. Primary outcome measures for stroke recovery trials
might separately address “motor recovery” or “cognitive
recovery,” or, more specifically, might address recovery of
arm function, gait, aphasia, etc. For example, to measure
upper extremity motor function, several tests are available,
including the Action Research Arm Test, Box and Blocks
Test, and arm motor subscale of the Fugl-Meyer scale, among
others.19,36 In phase II clinical trials, tests for several func-
tional domains can be chosen as end points, and the ones
providing the most promising results might be chosen as
primary outcome measures in pivotal trials. Current preclin-
ical models of stroke recovery emphasize sensorimotor over
cognitive recovery. If such models are used in the develop-
ment of stroke recovery treatments, then surely motor recov-
ery scales should be included as stand-alone outcome
measures in clinical trials. Major treatment-induced improve-
ments on modality-specific outcome measures should be
mirrored by improved quality of life, the ultimate standard of
treatment efficacy. Recent early-stage trials of stroke recov-
ery promoting-treatments have indeed adopted modality-
specific scales as primary outcome measures.17
Use of modality-specific outcome measures in clinical
trials of stroke recovery drugs may, in turn, result in
modality-specific “labeling” of treatments. Thus, for exam-
ple, a stroke recovery treatment would be approved as an
agent “to promote motor recovery,” “to promote cognitive
recovery,” or, more specifically, “to promote recovery of arm
function,” or “to promote recovery from aphasia” after stroke.
These deficits are common occurrences after stroke, insuring
a substantial market for such a product. In this regard,
approval of stroke recovery drugs may prove similar to
approval of Parkinson disease drugs, which are approved
primarily for efficacy on motor symptoms, or to approval of
Alzheimer disease drugs, which are approved primarily for
cognitive symptoms.
In addition to reliance on different outcome measures,
stroke recovery trials are likely to differ from acute stroke
trials is other significant ways. First, because stroke recovery
is a prolonged process occurring over weeks to months, the
time window for recruitment into such studies is likely to be
much longer than acute stroke trials, in which recruitment
windows are typically 0 to 6 hours after stroke. Second,
because of this longer time window to recruitment, patients
can be carefully selected by rigorous inclusion and exclusion
criteria, including demographic, imaging, and functional
criteria to achieve more homogeneity within treatment and
control groups.23 Third, because of the long time window to
recruitment, detailed baseline functional assessments of pa-
tients can be undertaken, against which repeated measures of
outcome assessments can be compared during the months
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after stroke. By relying on within-patient change scores as
primary outcome assessments, rather than a single cross-
sectional measurement taken at the end of the study period,
variance and thus clinical trial sample size requirements may
be substantially reduced. Because of considerable preclinical
data showing that functional recovery from brain injury or
stroke depends on repeated practice of the impaired functions,
concomitant behavioral treatments, including physical, occu-
pational, and speech therapies, will have to be controlled
carefully (or, at a minimum, recorded as covariates) in
clinical trials of stroke recovery-promoting agents.
In conclusion, because the clinical problem of stroke
recovery is distinct from that of acute stroke, we propose that
different strategies and designs are warranted for clinical
trials of stroke recovery treatments. Such designs will benefit
from the use of modality-specific outcome measures.
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